Table 2.
PsA clinical characteristics at baseline (effectiveness set)
| PsA characteristics | UST (n=438) | TNFi (n=455) |
| Psoriasis BSA, n (%) | ||
| Clear/almost clear skin | 102 (28.7) (24.1; 33.7) | 116 (33.0) (28.1; 38.1) |
| <3% but not clear/almost clear skin | 34 (9.6) (6.7; 13.1) | 53 (15.0) (11.5; 19.2) |
| 3‒10% | 124 (34.9) (30.0; 40.1) | 131 (37.2) (32.2; 42.5) |
| >10% | 95 (26.8) (22.2; 31.7) | 52 (14.8) (11.2; 18.9) |
| Axial involvement* – pure or combined with peripheral, n (%) | 153 (35.8) (31.3; 40.6) | 166 (37.4) (32.9; 42.1) |
| Oligoarticular†, n (%) | 96 (22.5) (18.6; 26.7) | 129 (29.1) (24.9; 33.5) |
| Polyarticular‡, n (%) | 286 (67.0) (62.3; 71.4) | 283 (63.7) (59.1; 68.2) |
| SJC66 | 5.9 (8.2) (5.1; 6.8) | 5.8 (7.5) (5.1; 6.6) |
| TJC68 | 12.5 (12.7) (11.2; 13.8) | 11.0 (10.5) (9.9; 12.0) |
| cDAPSA, n (%) | 30.6 (20.2) (28.5; 32.7) | 29.3 (18.6) (27.3; 31.2) |
| Remission | 10 (2.8) (1.3; 5.1) | 7 (2.0) (0.8; 4.0) |
| Low | 36 (10.1) (7.1; 13.6) | 39 (11.0) (7.9; 14.7) |
| Moderate | 141 (39.4) (34.3; 44.7) | 149 (41.9) (36.7; 47.2) |
| High | 171 (47.8) (42.5; 53.1) | 161 (45.2) (40.0; 50.6) |
| MDA§, n (%) | 16 (4.3) (2.5; 7.0) | 18 (5.1) (3.0; 7.9) |
| VLDA, n (%) | 1 (0.3)(0.0; 1.4) | 2 (0.5) (0.1; 2.0) |
| Enthesitis¶, n (%) | 192 (47.8) (42.8; 52.8) | 204 (51.3) (46.2; 56.3) |
| Dactylitis**, n (%) | 74 (17.7) (14.1; 21.7) | 90 (21.8) (17.9; 26.1) |
| PsAID-12 total score | 5.8 (2.1) (5.5; 6.0) | 5.5 (2.1) (5.3; 5.7) |
| HAQ-DI | 1.1 (0.7) (1.1; 1.2) | 1.2 (0.7) (1.1; 1.2) |
Data are mean (SD) (95% CI of the mean) unless otherwise stated; % is that of available data. Variables in bold indicate non-overlapping 95% CI.
*Pure axial PsA is defined as having only axial involvement (presence of axial disease declared by the treating rheumatologist without requirement for imaging), while combined axial PsA includes axial involvement and at least one of the following: distal interphalangeal joint involvement, monoarticular or oligoarticular PsA, polyarticular PsA, and arthritis mutilans. 2.1% of patients in the UST group and 3.2% in the TNFi group had pure axial PsA with inflammatory back pain.
†Either TJC68 and SJC66 are both non-missing and patient has <5 swollen or <5 tender joint counts, or in case TJC68 and/or SJC66 are missing monoarticular or oligoarticular PsA is indicated by the investigator.
‡Either TJC68 and SJC66 are both non-missing and patient has ≥5 swollen and ≥5 tender joint counts, or in case TJC68 and/or SJC66 are missing polyarticular PsA is indicated by the investigator.
§MDA includes VLDA.
¶Enthesitis presence defined as Leeds Enthesitis Index ≥0.
**Dactylitis presence on assessment of hands and feet.
BSA, body surface area; cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index; MDA, minimal disease activity; PsA, psoriatic arthritis; PsAID-12, 12-item Psoriatic Arthritis Impact of Disease; SJC66, swollen joint count for 66 joints; TJC68, tender joint count for 68 joints; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VLDA, very low disease activity.